Fri, April 26, 2024

Etzer Darout Maintained (ACRV) at Buy with Increased Target to $25 on, Apr 26th, 2024

Etzer Darout of BMO Capital, Maintained "Acrivon Therapeutics, Inc." (ACRV) at Buy with Increased Target from $18 to $25 on, Apr 26th, 2024.

Etzer has made no other calls on ACRV in the last 4 months.



There are 4 other peers that have a rating on ACRV. Out of the 4 peers that are also analyzing ACRV, 0 agree with Etzer's Rating of Hold.



These are the ratings of the 4 analyists that currently disagree with Etzer


  • Emily Bodnar of "HC Wainwright & Co." Reiterated at Strong Buy and Held Target at $20 on, Thursday, April 25th, 2024
  • Joseph Catanzaro of "Piper Sandler" Maintained at Buy with Increased Target to $30 on, Thursday, April 25th, 2024
  • Silvan Tuerkcan of "JMP Securities" Maintained at Buy with Increased Target to $17 on, Thursday, April 25th, 2024
  • Aydin Huseynov of "Ladenburg Thalmann" Maintained at Strong Buy with Decreased Target to $14 on, Friday, April 5th, 2024